Polyarteritis Nodosa
18
3
3
9
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
5.6%
1 terminated out of 18 trials
90.0%
+3.5% vs benchmark
11%
2 trials in Phase 3/4
11%
1 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (18)
Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
VCRC Tissue Repository
Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis
One-Time DNA Study for Vasculitis
Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis
Pediatric Vasculitis Initiative
Determining Disease Activity Biomarkers in Individuals With Polyarteritis Nodosa
VCRC Patient Contact Registry Patient-Reported Data Validation Study
Journey of Patients With Vasculitis From First Symptom to Diagnosis
American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis
Vasculitis Illness Perception (VIP) Study
Educational Needs of Patients With Systemic Vasculitis
Reproductive Health in Men and Women With Vasculitis
Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years
Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides
Lamivudine for Chronic Hepatitis B
CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors
Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases